The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...

Bristol Myers Squibb and Pfizer have launched an online programme to sell their blockbuster anticoagulant Eliquis directly to patients, following in the footsteps of Eli Lilly and Novo Nordisk in a ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series B backed by recent partner Eli Lilly. SanegeneBio, a biotech company with ...

Indian pharma group Wockhardt has completed a pre-filing meeting with the FDA and hopes to submit its new antibiotic Zaynich in the US and Europe later this year, eyeing a possible launch in fiscal ...

In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25 th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modified pig kidney, ...

The FDA has added a warning label to bluebird bio's Skysona, after launching an investigation into cases of blood cancer in patients treated with the ex vivo gene therapy last November. Skysona ...

AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...